Advertisement

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Welcome and Introduction to Vi3C

Amit Sanyal, MD: A Clinician’s Perspective

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

David A. Hyman, MD, JD, on Inclusive Shared Savings

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Advertisement

Advertisement

Jan

02

Today In Oncology

Study Explores Association of GLP-1 RAs With Risk of Obesity-Related Cancers

Noninferiority Shown for Pirtobrutinib vs Ibrutinib in CLL/SLL

Deb Schrag Elected 2027–2028 ASCO President

NSAIDs May Improve Survival in Postoperative ctDNA-Positive Patients With Colon Cancer

Molecular Analysis Reveals Underlying Sex-Linked Multiple Myeloma Progression Patterns

Advertisement

© 2026 HSP News Service, L.L.C.